Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
Top Page
aTyr Pharma
(NASDAQ:ATYR)
54Neutral
Positive Factors
Clinical Trials
The adjustment in the Phase 3 trial's primary endpoint to measure absolute change in steroid reduction is expected to favor the trial's success.
Financial Position
The company ended the quarter financially strong with $78.8 million in cash.
Valuation
Analyst's conservative valuation model suggests that the stock could rally 3X over the current trading price on positive Phase 3 data.
Negative Factors
Market Expectations
Now having critical Phase 3 data within 6 months represents an important potential trigger towards having aTyr appear on important fund screens.
Regulatory Pathway
As the clinical profile of AYTR2810 continues to mature, studies help crystallize a clinical and regulatory path forward, further de-risk the therapy, and increase the likelihood of success in future human studies.
Trial Execution
The lack of any major surprises in the baseline characteristics provide incremental reassurance on trial execution.
aTyr Pharma (ATYR) vs. S&P 500 (SPY)
Market Cap
$288.37M
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-100.00%
EPS Growth10.73%
CountryUS
Employees56
SectorHealthcare
Sector Strength48
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding89,004,430
10 Day Avg. Volume1,051,449
30 Day Avg. Volume1,270,921
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.00Price Target Upside593.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
aTyr Pharma Business Overview & Revenue Model
Company DescriptionaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
How the Company Makes MoneyaTyr Pharma makes money primarily through the development and commercialization of its proprietary therapeutic candidates. The company generates revenue through collaborations, licensing agreements, and potential sales of its developed therapies upon regulatory approval. Key revenue streams include milestone payments and royalties from partnerships with other pharmaceutical companies. Significant factors contributing to its earnings include the successful advancement of its product pipeline and strategic collaborations with industry partners to leverage expertise and resources in drug development and commercialization.
aTyr Pharma Financial Statement Overview
Summary
aTyr Pharma's financial performance faces significant challenges, with declining revenue, ongoing losses, and negative cash flows. Despite a strong equity position and low debt levels, the lack of profitability and cash flow generation presents long-term viability risks.Income Statement
aTyr Pharma's income statement shows significant challenges with sustained negative profitability. The gross profit margin was 100% in 2024 due to minimal revenue, but the company has a consistent negative net profit margin due to high expenses outweighing revenue, with a net income of -$64 million in 2024. Revenue growth was negative at -33.43% from 2023 to 2024, indicating a decline in sales. The EBIT and EBITDA margins are both negative, reflecting ongoing operational losses.35
Negative
Balance Sheet
The balance sheet shows a moderate financial position for aTyr Pharma. The debt-to-equity ratio is relatively low at 0.19, suggesting manageable leverage. However, the return on equity (ROE) is negative due to substantial net losses impacting shareholder value. The equity ratio stands at 72.33%, indicating a strong equity position relative to total assets.50
Neutral
Cash Flow
Cash flow analysis for aTyr Pharma reveals ongoing operational cash deficits, with an operating cash flow of -$69 million in 2024. The free cash flow growth rate is negative at -84.64%. The operating cash flow to net income ratio is slightly above 1, indicating operating losses are closely aligned with net income losses.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 235.00K | 353.00K | 10.39M | 0.00 | 10.46M | Gross Profit |
| 235.00K | -2.39M | 8.69M | -1.30M | -6.84M | EBIT |
| -67.91M | -54.92M | -46.40M | -34.02M | -15.91M | EBITDA |
| -66.37M | -52.18M | -44.71M | -32.47M | -14.64M | Net Income Common Stockholders |
| -64.02M | -50.39M | -45.34M | -33.77M | -16.22M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 72.13M | 98.17M | 66.15M | 107.91M | 31.69M | Total Assets |
| 96.83M | 120.65M | 95.79M | 115.54M | 38.73M | Total Debt |
| 13.28M | 15.10M | 11.53M | 1.38M | 2.24M | Net Debt |
| 2.23M | -7.45M | 1.55M | -958.00K | -14.71M | Total Liabilities |
| 27.00M | 30.18M | 24.50M | 6.41M | 7.24M | Stockholders Equity |
| 70.02M | 90.66M | 71.46M | 109.30M | 31.65M |
| Cash Flow | Free Cash Flow | |||
| -69.18M | -37.44M | -43.53M | -33.27M | -15.50M | Operating Cash Flow |
| -69.12M | -33.22M | -41.89M | -33.08M | -15.30M | Investing Cash Flow |
| 17.23M | -20.13M | 47.24M | -91.57M | 6.90M | Financing Cash Flow |
| 39.86M | 66.23M | 5.45M | 110.03M | 16.14M |
aTyr Pharma Technical Analysis
Positive
3.03
Price Trends
3.28
Positive
3.48
Negative
2.97
Positive
Market Momentum
0.02
Positive
50.53
Neutral
35.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Positive. The current price of 3.03 is below the 20-day moving average (MA) of 3.32, below the 50-day MA of 3.28, and above the 200-day MA of 2.97, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 50.53 is Neutral, neither overbought nor oversold. The STOCH value of 35.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 68 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $288.37M | ― | -79.51% | ― | -100.00% | 10.73% | |
52 Neutral | $5.22B | 3.55 | -44.39% | 2.82% | 15.40% | -0.09% | |
52 Neutral | $262.65M | 60.12 | 2.88% | ― | ― | 61.09% | |
46 Neutral | $314.33M | ― | -27.40% | ― | 15.40% | 35.42% | |
46 Neutral | $319.93M | ― | -39.07% | ― | ― | 0.42% | |
43 Neutral | $268.94M | ― | -46.01% | ― | ― | 9.22% | |
39 Underperform | $287.70M | ― | -62.43% | ― | -0.90% | -89.51% |
* Healthcare Sector Average
Performance Comparison
ATYR
aTyr Pharma
3.03
1.11
57.81%
ARCT
Arcturus Therapeutics
10.84
-18.18
-62.65%
OLMA
Olema Pharmaceuticals
4.68
-5.17
-52.49%
ATAI
ATAI Life Sciences
1.43
-0.62
-30.24%
GLUE
Monte Rosa Therapeutics
4.04
-1.19
-22.75%
AURA
Aura Biosciences Inc
4.90
-2.60
-34.67%
aTyr Pharma Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q4-2024)
| % Change Since: -4.11%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Q4-2024 Updates
Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Positive Safety Profile in Phase 3 Study
Four positive data and safety monitoring board reviews for EFZO-FIT identified no safety concerns, recommending the study to continue unmodified.
Increased Market Opportunity for Efzofitimod
Recent analysis shows the U.S. patient population for sarcoidosis is 30% higher than previously estimated, suggesting a larger market opportunity for efzofitimod.
Publication in Science Translational Medicine
An extensive manuscript on efzofitimod's mechanism of action and preclinical data was published in the journal Science Translational Medicine, validating its immunomodulatory properties.
Strong Financial Position and Cash Runway
aTyr ended 2024 with $75.1 million in cash and raised an additional $18.8 million, with a cash runway expected to fund operations through one year following the Phase 3 EFZO-FIT readout.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Potential Market Challenges
Despite potential market opportunities, current treatment practices indicate significant mortality and hospitalization rates, reflecting high unmet medical needs.
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Corporate Events
Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
aTyr Pharma Stockholders Approve Key Proposals at Annual Meeting
Neutral
May 6, 2025
At the recent Annual Meeting, aTyr Pharma‘s stockholders approved several key proposals, including the election of two Class I directors, the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025, and the approval of amendments to the 2015 Stock Plan. These decisions, supported by a significant number of votes, reflect the company’s strategic direction and governance priorities, potentially impacting its operational and financial strategies moving forward.
Spark’s Take on ATYR Stock
According to Spark, TipRanks’ AI Analyst, ATYR is a Neutral.
aTyr Pharma’s overall stock score reflects significant financial challenges, including ongoing losses and negative cash flows. Despite positive clinical developments and a strong cash position, the bearish technical indicators and negative valuation metrics weigh down the score. The earnings call offered promising guidance, but market challenges and limited clinical benchmarks pose risks.
To see Spark’s full report on ATYR stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.